extended

PreclinicalSmall molecule

UUniversity of Virginia

extended is one of 28 small molecule programs targeting Non-Hodgkin Lymphoma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Hodgkin LymphomaRecruiting

Non-Hodgkin LymphomaPreclinical

Recruiting

Competition

Competitive Landscape

34 competitors in Non-Hodgkin Lymphoma

#DrugCompanyPhaseTrials

Rituxan

Roche

Phase 3

5 2

LUNSUMIO

Roche

Phase 3

2 3

Polivy

Roche

Phase 3

2 4

Actemra

CCelltrion

Phase 3

3 5

Epkinly

Genmab

Phase 2

3 6

Adriamycin

Pfizer

Phase 2

1 7

Medrol

Pfizer

Phase 2

1 8

Revlimid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 2

3 9

Imbruvica

PPharmacyclics LLC.

Phase 2

2 10

Cytoxan

BBaxter Healthcare Corporation

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

PreclinicalRecruiting

Non-Hodgkin Lymphoma

NCT07730515

Clinical

Trials by Indication[1]

Liver Transplant1 trial

Surgical Site Infections After Liver Transplantation Based on Perioperative Antibiotics

Completed·UUniversity of Virginia·Phase 3·NCT02717273·102 enrolled

Non-Hodgkin Lymphoma1 trial

A Phase Ib/II Clinical Study of XNW5004 Combined With CHOP/CHOEP in the Treatment of Untreated Peripheral T-Cell Lymphoma

Recruiting·EEvopoint Biosciences Inc.·Preclinical·NCT07730515·176 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for extended. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — extended compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for extended. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Virginia company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity of Virginia

extended

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Liver Transplant1 trial

Non-Hodgkin Lymphoma1 trial

References

Drug Info

Quick Facts

Related News